--HC Wainwright Adjusts BioXcel Therapeutics' Price Target to $110 from $134, Keeps Buy Rating
10:47AM ET 5/23/2022 MT NewswiresPrice: 13.14, Change: -0.43, Percent Change: -3.21 ...
Price: 13.14, Change: -0.43, Percent Change: -3.21 ...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
...
BioXcel Therapeutics (BTAI) said Tuesday that it has created a wholly owned subsidiary called OnkosXcel Therapeutics, Inc. to develop transformative...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
BioXcel Therapeutics (BTAI) has an average rating of Buy and price targets ranging from $17 to $130, according to analysts polled by Capital IQ. (MT...
Health care stocks continued to add their Wednesday advance, with the NYSE Health Care Index and the SPDR Health Care Select Sector ETF (XLV) rising 1.9%...
Health care stocks were mostly higher this afternoon, with the NYSE Health Care Index and the SPDR Health Care Select Sector ETF (XLV) both rising 1.0%. ...
BioXcel Therapeutics (BTAI) has an average rating of Buy and price targets ranging from $16 to $130, according to analysts polled by Capital IQ. (MT...